Quoin Pharmaceuticals, Ltd.
QRX003
Netherton Syndrome
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews QRX003 for Netherton Syndrome around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 15h ago
“On January 27, 2026, Quoin submitted an application to Japan’s Ministry of Health, Labour and Welfare (MHLW) seeking Orphan Drug Designation for QRX003.”